Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by progressive loss of neuronal cell types and myelin sheath integrity across multiple brain regions. The neural circuit dysfunction in PSP involves a distributed network of [neurons](/entities/neurons) that collectively regulate eye movements, postural stability, gait, cognition, and autonomic functions. Understanding the circuit-level pathology provides insight into the characteristic clinical presentation of vertical supranuclear gaze palsy, early postural instability with falls, and frontal cognitive deficits[@chen2023][1].
The pathological hallmark of PSP is the accumulation of hyperphosphorylated [tau protein](/proteins/tau) (4-repeat tau) in neurofibrillary tangles, tufted [astrocytes](/entities/astrocytes), and swirling astrocytic plaques. These tau inclusions preferentially affect specific neuronal populations and their connections, creating a stereotyped pattern of circuit dysfunction that underlies the clinical phenotype of PSP. Recent work has demonstrated that tau pathology spreads trans-synaptically along neural circuits, explaining the predictable progression of symptoms[@barrett2021][2].
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by progressive loss of neuronal cell types and myelin sheath integrity across multiple brain regions. The neural circuit dysfunction in PSP involves a distributed network of [neurons](/entities/neurons) that collectively regulate eye movements, postural stability, gait, cognition, and autonomic functions. Understanding the circuit-level pathology provides insight into the characteristic clinical presentation of vertical supranuclear gaze palsy, early postural instability with falls, and frontal cognitive deficits[@chen2023][1].
The pathological hallmark of PSP is the accumulation of hyperphosphorylated [tau protein](/proteins/tau) (4-repeat tau) in neurofibrillary tangles, tufted [astrocytes](/entities/astrocytes), and swirling astrocytic plaques. These tau inclusions preferentially affect specific neuronal populations and their connections, creating a stereotyped pattern of circuit dysfunction that underlies the clinical phenotype of PSP. Recent work has demonstrated that tau pathology spreads trans-synaptically along neural circuits, explaining the predictable progression of symptoms[@barrett2021][2].
PSP exhibits significant clinical heterogeneity that maps to distinct patterns of circuit involvement[@stamelou2022]. The classic Richardson's syndrome (PSP-RS) represents the most common phenotype and involves the broadest circuit involvement. However, several variant syndromes have been recognized, each with characteristic circuit-specific pathology[3]:
PSP-Parkinsonism (PSP-P) presents with asymmetric onset and prominent parkinsonian features, reflecting more selective involvement of basal ganglia circuits without early brainstem oculomotor involvement. Patients with PSP-P show greater putaminal and globus pallidus involvement compared to PSP-RS, with relative preservation of brainstem structures early in the disease course.
Pure Akinesia with Gait Freezing (PAGF) represents a focal frontal variant characterized by predominant gait dysfunction with minimal ocular movement abnormalities. This phenotype correlates with preferential tau pathology in the supplementary motor area and premotor cortex, with relative sparing of brainstem oculomotor nuclei.
Corticobasal Syndrome (CBS) Variant demonstrates asymmetric cortical and basal ganglia involvement, reflecting frontoparietal circuit pathology. The presence of cortical signs such as apraxia, alien limb, and cortical sensory loss distinguishes this variant and indicates more extensive cortical involvement[4].
Frontal Presentation (PSP-F) features predominant executive dysfunction and behavioral changes with early frontal circuit involvement. This variant shows prominent tau pathology in the dorsolateral prefrontal cortex and anterior cingulate, with relative preservation of brainstem structures initially.
The characteristic symptoms of PSP can be understood through their circuit correlates:
| Symptom | Primary Circuit | Key Structures |
|---------|-----------------|-----------------|
| Vertical gaze palsy | Oculomotor brainstem | Superior colliculus, MLF, CN III/IV nuclei |
| Postural instability | Vestibulospinal | Reticular formation, vestibular nuclei |
| Gait freezing | Fronto-striatal | Pre-SMA, SMA, striatum |
| Bradykinesia | Basal ganglia motor loop | Putamen, GPi, STN |
| Dysarthria | Bulbar motor | Brainstem nuclei, cerebellum |
| Cognitive decline | Prefrontal circuits | DLPFC, ACC, caudate nucleus |
| Apathy | Limbic circuits | Anterior cingulate, orbitofrontal |
The superior colliculus plays a critical role in initiating saccadic eye movements and is heavily implicated in PSP pathology. The intermediate layer of the superior colliculus receives input from the frontal eye fields (Brodmann area 8) and the supplementary eye field, representing the cortical command for voluntary saccades. In PSP, tau pathology disrupts the inhibitory interneurons that normally suppress unwanted saccades, contributing to the characteristic square-wave jerks and slow saccades that precede the development of complete vertical supranuclear gaze palsy[2].
The omnipause neuron system, which provides critical gating control for saccadic initiation, shows significant degeneration in PSP. These neurons, located in the raphe interpositus nucleus and the nucleus of the posterior commissure, normally fire continuously during fixation and pause during saccades. Their degeneration in PSP removes this braking mechanism, resulting in pathological saccade sequences and the clinical finding of slowed vertical saccades.
The vertical gaze center, located in the midbrain reticular formation adjacent to the posterior commissure, coordinates vertical eye movements through connections with the oculomotor (CN III) and trochlear (CN IV) nuclei. The medial longitudinal fasciculus (MLF) carries signals between the vertical gaze center and the nuclei controlling vertical eye movement. In PSP, tau pathology in the periaqueductal gray and the MLF disrupts these connections, causing the characteristic vertical supranuclear gaze palsy that first manifests as difficulty looking downward[3].
The parabigeminal nucleus and the pedunculopontine nucleus, both involved in eye movement control, show early tau pathology in PSP. The pedunculopontine nucleus also plays a critical role in arousal and REM sleep generation, and its involvement may contribute to the sleep disturbances commonly reported in PSP patients.
PSP pathology involves multiple basal ganglia circuits that regulate movement initiation, motor execution, and cognitive functions. The direct pathway, which facilitates movement through disinhibition of the thalamus, shows reduced activity due to tau-mediated degeneration of striatal projection neurons. The indirect pathway, which normally suppresses competing motor programs, becomes relatively overactive, contributing to the bradykinesia and rigidity observed in PSP[4].
The subthalamic nucleus, a key node in the indirect pathway, demonstrates significant tau pathology in PSP. Hyperactivity in this nucleus drives excessive inhibition of the thalamus, further exacerbating motor deficits. This understanding has led to experimental treatments targeting subthalamic nucleus activity in PSP.
PSP disrupts multiple corticostriatal loops that normally integrate motor, oculomotor, prefrontal, and limbic information. The dorsolateral prefrontal circuit, involved in executive function and working memory, shows early impairment due to caudate nucleus degeneration. The anterior cingulate circuit, involved in error detection and motivation, is disrupted by ACC degeneration, contributing to apathy and reduced emotional reactivity in PSP[5].
The oculomotor circuit, connecting the frontal eye fields through the caudate and substantia nigra pars reticulata to the thalamus and superior colliculus, is specifically affected, causing the characteristic eye movement abnormalities.
The prefrontal cortex plays a critical role in PSP pathophysiology, with multiple frontal circuits showing early involvement. The dorsolateral prefrontal circuit, mediated by the dorsolateral portion of the caudate nucleus, shows particular vulnerability, leading to the executive dysfunction characteristic of PSP. Patients demonstrate impaired working memory, reduced cognitive flexibility, and difficulty with planning and organization—symptoms that correlate with reduced activation in the DLPFC on functional neuroimaging[7].
The anterior cingulate circuit, centered on the anterior cingulate cortex (ACC) and its connections to the ventromedial striatum, is frequently affected in PSP. ACC pathology contributes to apathy, reduced emotional reactivity, and decreased motivation. The ACC also plays a critical role in error detection and conflict monitoring, and its dysfunction explains the impaired performance on conflict tasks observed in PSP patients.
The orbitofrontal circuit, involved in behavioral inhibition and reward processing, shows early involvement in PSP. Patients demonstrate disinhibition, inappropriate social behavior, and altered reward sensitivity. This circuit connects the orbitofrontal cortex with the ventromedial striatum and mediodorsal thalamus.
The cerebellum participates in ocular motor control through the ventral paraflocculus and the flocculus, which mediate smooth pursuit and vestibulo-ocular reflex gain adaptation. PSP patients show significant impairment of these functions due to tau pathology in the cerebellar nuclei and their brainstem connections[6].
The cerebellar thalamic pathway, connecting the deep cerebellar nuclei to the ventrolateral thalamic nuclei, provides excitatory drive to the motor [cortex](/brain-regions/cortex). Degeneration of this pathway in PSP contributes to axial rigidity and the characteristic stiff-neck posture.
The deep cerebellar nuclei (DCN), particularly the dentate nucleus, project via the thalamus to the frontal cortex, forming the cerebello-thalamo-cortical circuit. This pathway is critical for coordinating movement timing and force regulation. In PSP, tau pathology in the dentate nucleus disrupts this coordination, contributing to the clumsiness and misiming of movements observed in patients.
The cerebellar flocculus and ventral paraflocculus maintain the vestibulo-ocular reflex (VOR), which stabilizes gaze during head movements. PSP patients show reduced VOR gain, contributing to gaze instability and impaired visual tracking. This manifests clinically as difficulty reading and following moving objects.
Beyond motor control, the cerebellum participates in cognitive circuits through its connections with the prefrontal cortex via the pontine nuclei and thalamus. The cerebellar cognitive affective syndrome, characterized by executive dysfunction, linguistic impairment, and emotional dysregulation, has been described in PSP patients with significant cerebellar involvement[6].
PSP pathology extends to critical brainstem autonomic centers, contributing to the prominent autonomic dysfunction seen in this disorder. The nucleus of the solitary tract (NTS), which processes visceromotor and viscerosensory information, shows early tau pathology. This contributes to dysregulated blood pressure control, orthostatic hypotension, and dysphagia.
The dorsal motor nucleus of the vagus, which provides parasympathetic innervation to the heart and gastrointestinal tract, demonstrates significant involvement in PSP. This explains the high prevalence of constipation, gastroparesis, and cardiac rhythm disturbances in PSP patients.
The locus coeruleus, the principal noradrenergic nucleus, is heavily affected in PSP. This central autonomic hub normally modulates arousal, attention, and autonomic tone. Its degeneration contributes to daytime somnolence, sleep fragmentation, and impaired autonomic responses to stress.
The central autonomic network (CAN) integrates hypothalamic, brainstem, and cortical inputs to regulate autonomic function. PSP disrupts CAN integrity through tau pathology in the hypothalamus, parabrachial nucleus, and periaqueductal gray. This manifests as:
Deep brain stimulation (DBS) has been explored as a treatment for PSP, with several targets under investigation. The subthalamic nucleus and the globus pallidus internus have been targeted in small pilot studies, with variable results. The most promising outcomes have been observed with stimulation of the pedunculopontine nucleus, which has shown improvements in gait and postural stability in some PSP patients[6].
Recent approaches have explored targeting multiple nodes simultaneously, recognizing that PSP involves distributed circuit dysfunction rather than a single focal abnormality. This multi-target approach aims to modulate the networks most affected by tau pathology.
Tau-directed therapies aim to reduce tau aggregation or enhance tau clearance, potentially stabilizing affected circuits. Several agents targeting tau phosphorylation, aggregation, or misfolding are in clinical development. The goal of these interventions is to halt further circuit degradation rather than reverse existing damage[14].
Dopaminergic agents provide symptomatic benefit for some PSP patients, particularly those with parkinsonian features. However, the response is typically less robust than in [Parkinson's disease](/diseases/parkinsons-disease), reflecting the broader circuit involvement in PSP.
Recent advances in understanding PSP circuit dysfunction have opened new therapeutic avenues:
Anti-tau monoclonal antibodies such as gosuranemab and tilavonemab target extracellular tau aggregates and have shown promise in Phase 2 trials for reducing CSF tau biomarkers. These therapies may slow circuit degeneration by preventing tau propagation between neurons.
Small molecule tau aggregation inhibitors aim to prevent the formation of tau oligomers and fibrils. The goal is to stabilize synaptic function and prevent trans-synaptic spread of pathology along affected circuits.
Neurotrophic factor delivery through gene therapy approaches aims to support neuronal survival in affected circuits. Delivery of BDNF or GDNF to the striatum and basal ganglia may enhance circuit function and neuroplasticity.
Circuit-specific neuromodulation using targeted ultrasound or optogenetic approaches represents a frontier for precisely modulating specific neural circuits affected in PSP.
MRI shows characteristic midbrain atrophy in PSP, with the "hummingbird sign" representing tegmental degeneration surrounding the third ventricle. Diffusion tensor imaging reveals reduced integrity of the superior colliculus-to-frontal eye field pathway, correlating with saccadic velocity. Functional MRI shows reduced activation in the frontal eye fields during saccade tasks[8].
PET imaging with tau ligands demonstrates increased tau tracer retention in the brainstem, basal ganglia, and frontal cortex, corresponding to the distribution of circuit pathology. This imaging approach may help diagnose PSP earlier and monitor disease progression.
Eye movement recordings provide quantitative measures of circuit dysfunction in PSP. Saccadic velocity, particularly vertical saccades, correlates with disease severity and progression. The antisaccade task, which requires withholding a reflexive response and generating a voluntary saccade, reveals executive circuit dysfunction in PSP.
The following diagram shows the key molecular relationships involving Progressive Supranuclear Palsy Neural Circuit discovered through SciDEX knowledge graph analysis: